Literature DB >> 19516253

Influence of CYP3A and CYP2C19 genetic polymorphisms on the pharmacokinetics of cilostazol in healthy subjects.

H-D Yoo1, S-A Park, H-Y Cho, Y-B Lee.   

Abstract

The objective of this study was to investigate the influence of genetic polymorphisms in the CYP3A and CYP2C19 genes on cilostazol pharmacokinetics, with the drug being administered orally as a 50-mg single dose in healthy subjects. CYP2C19 genotypes in individuals with the CYP3A5*3/*3 genotype were associated with statistically significant differences (P < 0.05) in cilostazol pharmacokinetics parameters (apparent oral clearance (CL/F) and terminal half-life (t(1/2))). This indicates that CYP2C19 polymorphisms play an important role in the metabolism of cilostazol only in individuals with the CYP3A5*3/*3 genotype, which has low metabolic activity.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19516253     DOI： 10.1038/clpt.2009.90

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  8 in total

1.  Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study.

Authors:  In-Suk Kim; Young-Hoon Jeong; Yongwhi Park; Seong-Eun Yoon; Tae Jung Kwon; Jeong Rang Park; Seok-Jae Hwang; Eun-Ha Koh; Choong Hwan Kwak; Jin-Yong Hwang; Sunjoo Kim
Journal:  Br J Clin Pharmacol       Date:  2012-04       Impact factor: 4.335

2.  Effects of CYP2C19 and CYP3A5 genetic polymorphisms on the pharmacokinetics of cilostazol and its active metabolites.

Authors:  Hye-In Lee; Ji-Young Byeon; Young-Hoon Kim; Choong-Min Lee; Chang-Ik Choi; Choon-Gon Jang; Jung-Woo Bae; Yun Jeong Lee; Seok-Yong Lee
Journal:  Eur J Clin Pharmacol       Date:  2018-07-24       Impact factor: 2.953

Review 3.  Platelet Signaling and Disease: Targeted Therapy for Thrombosis and Other Related Diseases.

Authors:  Jennifer Yeung; Wenjie Li; Michael Holinstat
Journal:  Pharmacol Rev       Date:  2018-07       Impact factor: 25.468

4.  The pharmacokinetic and pharmacodynamic interaction of clopidogrel and cilostazol in relation to CYP2C19 and CYP3A5 genotypes.

Authors:  Ho-Sook Kim; Younghae Lim; Minkyung Oh; Jong-Lyul Ghim; Eun-Young Kim; Dong-Hyun Kim; Jae-Gook Shin
Journal:  Br J Clin Pharmacol       Date:  2015-12-28       Impact factor: 4.335

5.  Population pharmacokinetic analysis of cilostazol in healthy subjects with genetic polymorphisms of CYP3A5, CYP2C19 and ABCB1.

Authors:  Hee-Doo Yoo; Hea-Young Cho; Yong-Bok Lee
Journal:  Br J Clin Pharmacol       Date:  2010-01       Impact factor: 4.335

6.  In vivo quantitative prediction of the effect of gene polymorphisms and drug interactions on drug exposure for CYP2C19 substrates.

Authors:  Sylvain Goutelle; Laurent Bourguignon; Nathalie Bleyzac; Johanna Berry; Fannie Clavel-Grabit; Michel Tod
Journal:  AAPS J       Date:  2013-01-15       Impact factor: 4.009

7.  Pharmacokinetic properties of two erlotinib 150 mg formulations with a genetic effect evaluation in healthy Korean subjects.

Authors:  Hyun-Gyu Choi; Ji-Young Jeon; Yong-Jin Im; Yunjeong Kim; Eun-Kee Song; Young-Hwan Seo; Seok-Je Cho; Min-Gul Kim
Journal:  Clin Drug Investig       Date:  2015-01       Impact factor: 3.580

8.  The Efficacy and Safety of Cilostazol vs. Aspirin for Secondary Stroke Prevention: A Systematic Review and Meta-Analysis.

Authors:  Erqing Chai; Jinhua Chen; Changqing Li; Xue Zhang; Zhiqiang Fan; Shijie Yang; Kaixuan Zhao; Wei Li; Zaixing Xiao; Yichuan Zhang; Futian Tang
Journal:  Front Neurol       Date:  2022-02-15       Impact factor: 4.003
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.